ONTOLOGY REPORT - ANNOTATIONS
| Term: | N-methyl-N-nitrosurea |
|
| Accession: | CHEBI:50102
|
browse the term
|
| Definition: | An urea that has formula C2H5N3O2. |
| Synonyms: | exact_synonym: | 1-methyl-1-nitrosourea |
| | related_synonym: | 1-(aminocarbonyl)-1-methyl-2-oxohydrazine; 1-nitroso-1-methylurea; C2H5N3O2; CN(N=O)C(N)=O; InChI=1S/C2H5N3O2/c1-5(4-7)2(3)6/h1H3,(H2,3,6); InChIKey=ZRKWMRDKSOPRRS-UHFFFAOYSA-N; MNU; Methylnitrosoharnstoff; Methylnitrosourea; N-Methyl-N-nitrosoharnstoff; N-Methyl-N-nitrosourea; N-Nitroso-N-methylharnstoff; N-methyl-N-nitrosocarbamide; N-methyl-N-nitrosouree; N-nitroso-N-methylcarbamide; N-nitroso-N-methylurea; N-nitroso-N-methyluree; N-nitrosomethylurea; NMH; NMU; methylnitrosouree; nitrosomethylurea |
| | alt_id: | CHEBI:25565; CHEBI:34843; CHEBI:50101 |
| | xref_casrn: | 684-93-5 |
| | xref: | Beilstein:1756040 "Beilstein Registry Number"; ChEMBL:153679 "ChEMBL COMPOUND"; ChemIDplus:684-93-5 "CAS Registry Number"; KEGG COMPOUND:684-93-5 "CAS Registry Number"; KEGG COMPOUND:C14595 "KEGG COMPOUND" |
| | xref_mesh: | MESH:D008770 |
| | xref: | NIST Chemistry WebBook:684-93-5 "CAS Registry Number" |
|
|
N-methyl-N-nitrosurea
|
| G |
Acly |
ATP citrate lyase |
|
increases expression |
EXP |
10 |
89,420,934 |
89,471,398 |
RGD:6480464 |
CTD |
| G |
Actb |
actin, beta |
|
increases mutagenesis |
EXP |
12 |
12,047,070 |
12,050,040 |
RGD:6480464 |
CTD |
| G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
increases expression |
EXP |
11 |
25,434,262 |
25,443,144 |
RGD:6480464 |
CTD |
| G |
Afp |
alpha-fetoprotein |
|
decreases response to substance |
EXP |
14 |
19,092,563 |
19,110,728 |
RGD:6480464 |
CTD |
| G |
Agtr1b |
angiotensin II receptor, type 1b |
|
increases expression |
EXP |
2 |
105,503,269 |
105,602,591 |
RGD:6480464 |
CTD |
| G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
|
increases expression |
EXP |
4 |
61,714,282 |
61,726,856 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt2 |
v-akt murine thymoma viral oncogene homolog 2 |
|
multiple interactions |
EXP |
1 |
82,686,233 |
82,726,544 |
RGD:6480464 |
CTD |
| G |
Angptl4 |
angiopoietin-like 4 |
|
increases expression |
EXP |
7 |
16,261,623 |
16,267,852 |
RGD:6480464 |
CTD |
| G |
Apc |
adenomatous polyposis coli |
|
increases response to substance |
ISO |
18 |
26,732,147 |
26,790,383 |
RGD:6480464 |
CTD |
| G |
Asip |
agouti signaling protein |
|
increases mutagenesis |
ISO |
3 |
145,445,175 |
145,536,831 |
RGD:6480464 |
CTD |
| G |
Asip |
agouti signaling protein |
|
increases mutagenesis |
ISO |
3 |
145,445,175 |
145,536,831 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
decreases expression |
EXP |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Atp6v1f |
ATPase, H transporting, lysosomal V1 subunit F |
|
increases mutagenesis |
ISO |
4 |
56,347,184 |
56,350,085 |
RGD:6480464 |
CTD |
| G |
Atr |
ataxia telangiectasia and Rad3 related |
|
affects localization |
ISO |
8 |
100,936,342 |
101,014,881 |
RGD:6480464 |
CTD |
| G |
Atr |
ataxia telangiectasia and Rad3 related |
|
multiple interactions |
ISO |
8 |
100,936,342 |
101,014,881 |
RGD:6480464 |
CTD |
| G |
Atr |
ataxia telangiectasia and Rad3 related |
|
affects localization |
ISO |
8 |
100,936,342 |
101,014,881 |
RGD:6480464 |
CTD |
| G |
Atr |
ataxia telangiectasia and Rad3 related |
|
multiple interactions |
ISO |
8 |
100,936,342 |
101,014,881 |
RGD:6480464 |
CTD |
| G |
Aurka |
aurora kinase A |
|
multiple interactions |
EXP |
3 |
163,270,479 |
163,284,506 |
RGD:6480464 |
CTD |
| G |
Aurka |
aurora kinase A |
|
increases expression |
EXP |
3 |
163,270,479 |
163,284,506 |
RGD:6480464 |
CTD |
| G |
B3galt1 |
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 |
|
increases expression |
EXP |
3 |
50,146,767 |
50,160,110 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl10 |
B-cell CLL/lymphoma 10 |
|
increases expression |
EXP |
2 |
244,116,880 |
244,126,393 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bmp5 |
bone morphogenetic protein 5 |
|
increases mutagenesis |
ISO |
8 |
80,593,053 |
80,717,015 |
RGD:6480464 |
CTD |
| G |
Bmp5 |
bone morphogenetic protein 5 |
|
increases mutagenesis |
ISO |
8 |
80,593,053 |
80,717,015 |
RGD:6480464 |
CTD |
| G |
Bpnt1 |
3'(2'), 5'-bisphosphate nucleotidase 1 |
|
increases mutagenesis |
ISO |
13 |
101,340,544 |
101,367,549 |
RGD:6480464 |
CTD |
| G |
Btg2 |
BTG family, member 2 |
|
increases expression |
ISO |
13 |
47,026,986 |
47,030,745 |
RGD:6480464 |
CTD |
| G |
Ca2 |
carbonic anhydrase 2 |
|
increases expression |
EXP |
2 |
88,077,095 |
88,092,223 |
RGD:6480464 |
CTD |
| G |
Capn1 |
calpain 1, (mu/I) large subunit |
|
decreases activity |
EXP |
1 |
208,620,286 |
208,645,007 |
RGD:6480464 |
CTD |
| G |
Capn2 |
calpain 2, (m/II) large subunit |
|
increases activity |
EXP |
13 |
98,473,367 |
98,524,463 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cbr1 |
carbonyl reductase 1 |
|
increases expression |
EXP |
11 |
33,787,957 |
33,790,320 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
increases expression |
EXP |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Ccl4 |
chemokine (C-C motif) ligand 4 |
|
increases expression |
EXP |
10 |
71,759,643 |
71,761,115 |
RGD:6480464 |
CTD |
| G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
|
increases expression |
ISO |
10 |
71,605,791 |
71,610,330 |
RGD:6480464 |
CTD |
| G |
Ccna2 |
cyclin A2 |
|
increases expression |
ISO |
2 |
123,062,752 |
123,069,085 |
RGD:6480464 |
CTD |
| G |
Ccna2 |
cyclin A2 |
|
decreases expression |
ISO |
2 |
123,062,752 |
123,069,085 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd3 |
cyclin D3 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cd59 |
CD59 molecule, complement regulatory protein |
|
multiple interactions |
EXP |
3 |
89,243,600 |
89,245,129 |
RGD:6480464 |
CTD |
| G |
Cd59 |
CD59 molecule, complement regulatory protein |
|
multiple interactions |
EXP |
3 |
89,243,600 |
89,245,129 |
RGD:6480464 |
CTD |
| G |
Cdh22 |
cadherin 22 |
|
decreases expression |
EXP |
3 |
156,155,004 |
156,275,540 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
decreases expression |
ISO |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
increases expression |
EXP |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
increases expression |
ISO |
20 |
20,018,044 |
20,044,030 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
increases activity |
EXP |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk5r1 |
cyclin-dependent kinase 5, regulatory subunit 1 (p35) |
|
increases cleavage |
EXP |
10 |
68,715,844 |
68,717,045 |
RGD:6480464 |
CTD |
| G |
Cdk5rap1 |
CDK5 regulatory subunit associated protein 1 |
|
increases mutagenesis |
ISO |
3 |
144,803,213 |
144,840,056 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
decreases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cel |
carboxyl ester lipase |
|
increases expression |
ISO |
3 |
7,541,127 |
7,549,245 |
RGD:6480464 |
CTD |
| G |
Cela2a |
chymotrypsin-like elastase family, member 2A |
|
increases expression |
ISO |
5 |
160,722,053 |
160,731,804 |
RGD:6480464 |
CTD |
| G |
Cep290 |
centrosomal protein 290 |
|
decreases expression |
EXP |
7 |
38,138,545 |
38,228,716 |
RGD:6480464 |
CTD |
| G |
Chek2 |
checkpoint kinase 2 |
|
increases phosphorylation |
ISO |
12 |
45,933,900 |
45,965,427 |
RGD:6480464 |
CTD |
| G |
Chek2 |
checkpoint kinase 2 |
|
multiple interactions |
ISO |
12 |
45,933,900 |
45,965,427 |
RGD:6480464 |
CTD |
| G |
Cldn7 |
claudin 7 |
|
decreases expression |
EXP |
10 |
56,810,947 |
56,813,134 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
increases expression |
EXP |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Col4a3 |
collagen, type IV, alpha 3 |
|
decreases expression |
EXP |
9 |
81,910,656 |
82,036,998 |
RGD:6480464 |
CTD |
| G |
Col5a3 |
collagen, type V, alpha 3 |
|
decreases expression |
EXP |
8 |
19,789,061 |
19,834,241 |
RGD:6480464 |
CTD |
| G |
Cradd |
CASP2 and RIPK1 domain containing adaptor with death domain |
|
increases mutagenesis |
ISO |
7 |
32,504,279 |
32,517,581 |
RGD:6480464 |
CTD |
| G |
Crem |
cAMP responsive element modulator |
|
increases expression |
EXP |
17 |
62,770,633 |
62,837,670 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
increases expression |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Ctgf |
connective tissue growth factor |
|
decreases expression |
EXP |
1 |
21,327,099 |
21,330,215 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
increases expression |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Cxcr1 |
chemokine (C-X-C motif) receptor 1 |
|
increases mutagenesis |
ISO |
9 |
73,510,488 |
73,511,537 |
RGD:6480464 |
CTD |
| G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp2j3 |
cytochrome P450, family 2, subfamily j, polypeptide 3 |
|
decreases expression |
EXP |
5 |
116,744,337 |
116,766,822 |
RGD:6480464 |
CTD |
| G |
Dbi |
diazepam binding inhibitor (GABA receptor modulator, acyl-CoA binding protein) |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Dbp |
D site of albumin promoter (albumin D-box) binding protein |
|
decreases expression |
EXP |
1 |
96,173,573 |
96,178,485 |
RGD:6480464 |
CTD |
| G |
Depdc7 |
DEP domain containing 7 |
|
increases expression |
EXP |
3 |
90,054,620 |
90,075,902 |
RGD:6480464 |
CTD |
| G |
Dio1 |
deiodinase, iodothyronine, type I |
|
multiple interactions |
EXP |
5 |
128,385,702 |
128,404,015 |
RGD:6480464 |
CTD |
| G |
Dlgap1 |
discs, large (Drosophila) homolog-associated protein 1 |
|
increases mutagenesis |
ISO |
9 |
109,455,911 |
110,018,738 |
RGD:6480464 |
CTD |
| G |
Dmbt1 |
deleted in malignant brain tumors 1 |
|
increases expression |
ISO |
1 |
190,378,428 |
190,470,536 |
RGD:6480464 |
CTD |
| G |
Dnpep |
aspartyl aminopeptidase |
|
decreases activity |
EXP |
9 |
74,586,544 |
74,595,414 |
RGD:6480464 |
CTD |
| G |
Dusp5 |
dual specificity phosphatase 5 |
|
increases expression |
EXP |
1 |
259,754,234 |
259,767,645 |
RGD:6480464 |
CTD |
| G |
Dym |
dymeclin |
|
increases mutagenesis |
ISO |
18 |
71,889,053 |
72,188,251 |
RGD:6480464 |
CTD |
| G |
Ech1 |
enoyl CoA hydratase 1, peroxisomal |
|
increases mutagenesis |
ISO |
1 |
83,932,720 |
83,938,918 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
increases mutagenesis |
ISO |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Eed |
embryonic ectoderm development |
|
affects response to substance |
ISO |
1 |
146,563,961 |
146,591,042 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
multiple interactions |
EXP |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Elovl6 |
ELOVL fatty acid elongase 6 |
|
increases expression |
EXP |
2 |
226,946,573 |
227,054,321 |
RGD:6480464 |
CTD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
increases expression |
ISO |
13 |
96,722,973 |
96,752,940 |
RGD:6480464 |
CTD |
| G |
Ercc4 |
excision repair cross-complementing rodent repair deficiency, complementation group 4 |
|
decreases expression |
ISO |
10 |
2,144,262 |
2,177,554 |
RGD:6480464 |
CTD |
| G |
Ercc4 |
excision repair cross-complementing rodent repair deficiency, complementation group 4 |
|
increases expression |
ISO |
10 |
2,144,262 |
2,177,554 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
EXP |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
increases response to substance |
EXP |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
EXP |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
decreases phosphorylation |
EXP |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Ezr |
ezrin |
|
increases expression |
EXP |
1 |
41,178,195 |
41,221,735 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
increases expression |
EXP |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
Fabp3 |
fatty acid binding protein 3, muscle and heart |
|
increases expression |
EXP |
5 |
149,340,525 |
149,347,268 |
RGD:6480464 |
CTD |
| G |
Faim2 |
Fas apoptotic inhibitory molecule 2 |
|
increases expression |
EXP |
7 |
138,246,372 |
138,272,190 |
RGD:6480464 |
CTD |
| G |
Fasn |
fatty acid synthase |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
multiple interactions |
EXP |
18 |
31,785,480 |
31,806,452 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
multiple interactions |
EXP |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
multiple interactions |
EXP |
1 |
189,482,975 |
189,589,279 |
RGD:6480464 |
CTD |
| G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
multiple interactions |
EXP |
17 |
15,512,144 |
15,527,348 |
RGD:6480464 |
CTD |
| G |
Fhit |
fragile histidine triad |
|
decreases expression |
EXP |
15 |
15,823,461 |
17,329,184 |
RGD:6480464 |
CTD |
| G |
Fhit |
fragile histidine triad |
|
decreases expression |
EXP |
15 |
15,823,461 |
17,329,184 |
RGD:6480464 |
CTD |
| G |
Fhit |
fragile histidine triad |
|
increases methylation |
EXP |
15 |
15,823,461 |
17,329,184 |
RGD:6480464 |
CTD |
| G |
Fhit |
fragile histidine triad |
|
decreases expression |
EXP |
15 |
15,823,461 |
17,329,184 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
multiple interactions |
EXP |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
decreases expression |
EXP |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Galnt16 |
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 16 |
|
increases mutagenesis |
ISO |
6 |
104,285,081 |
104,366,257 |
RGD:6480464 |
CTD |
| G |
Gbp2 |
guanylate binding protein 2, interferon-inducible |
|
increases expression |
EXP |
2 |
240,523,000 |
240,541,078 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
increases expression |
EXP |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases response to substance |
EXP |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gjb1 |
gap junction protein, beta 1 |
|
decreases response to substance |
ISO |
X |
89,448,873 |
89,456,812 |
RGD:6480464 |
CTD |
| G |
Gpx2 |
glutathione peroxidase 2 |
|
increases expression |
EXP |
6 |
99,372,418 |
99,376,230 |
RGD:6480464 |
CTD |
| G |
Grb14 |
growth factor receptor bound protein 14 |
|
increases mutagenesis |
ISO |
3 |
46,832,380 |
46,952,670 |
RGD:6480464 |
CTD |
| G |
Hba1 |
hemoglobin, alpha 1 |
|
increases carbamoylation |
ISO |
10 |
15,584,360 |
15,585,215 |
RGD:6480464 |
CTD |
| G |
Hba2 |
hemoglobin, alpha 2 |
|
increases carbamoylation |
ISO |
10 |
15,570,930 |
15,571,773 |
RGD:6480464 |
CTD |
| G |
Hbb |
hemoglobin, beta |
|
increases carbamoylation |
ISO |
1 |
161,618,782 |
161,620,193 |
RGD:6480464 |
CTD |
| G |
Hesx1 |
HESX homeobox 1 |
|
increases mutagenesis |
ISO |
16 |
2,255,128 |
2,257,233 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
multiple interactions |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hgf |
hepatocyte growth factor |
|
decreases expression |
ISO |
4 |
14,864,357 |
14,932,513 |
RGD:6480464 |
CTD |
| G |
Hivep2 |
human immunodeficiency virus type I enhancer binding protein 2 |
|
increases expression |
EXP |
1 |
8,783,016 |
9,032,351 |
RGD:6480464 |
CTD |
| G |
Hmgb2 |
high mobility group box 2 |
|
increases expression |
EXP |
16 |
36,131,304 |
36,133,878 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
|
increases mutagenesis |
EXP |
X |
139,929,647 |
139,961,616 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
multiple interactions |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
decreases response to substance |
EXP |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases mutagenesis |
EXP |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases mutagenesis |
EXP |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
increases response to substance |
ISO |
1 |
201,385,705 |
201,388,987 |
RGD:6480464 |
CTD |
| G |
Ier3 |
immediate early response 3 |
|
increases expression |
EXP |
20 |
3,076,568 |
3,077,772 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
decreases response to substance |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
decreases response to substance |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifrd1 |
interferon-related developmental regulator 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ifrd1 |
interferon-related developmental regulator 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
increases response to substance |
ISO |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
multiple interactions |
EXP |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
increases expression |
EXP |
1 |
122,704,976 |
122,990,007 |
RGD:6480464 |
CTD |
| G |
Ighe |
immunoglobulin heavy chain (epsilon polypeptide) |
|
increases mutagenesis |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ikzf1 |
IKAROS family zinc finger 1 |
|
decreases expression |
ISO |
14 |
92,560,200 |
92,657,336 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
multiple interactions |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
decreases expression |
ISO |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
increases expression |
EXP |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il17b |
interleukin 17B |
|
increases expression |
EXP |
18 |
57,665,293 |
57,669,668 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
increases expression |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
EXP |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
multiple interactions |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Il4 |
interleukin 4 |
|
increases expression |
ISO |
10 |
39,074,582 |
39,080,134 |
RGD:6480464 |
CTD |
| G |
Inadl |
InaD-like (Drosophila) |
|
increases expression |
ISO |
5 |
118,806,744 |
119,131,114 |
RGD:6480464 |
CTD |
| G |
Insr |
insulin receptor |
|
increases expression |
EXP |
12 |
2,934,967 |
3,087,691 |
RGD:6480464 |
CTD |
| G |
Irf1 |
interferon regulatory factor 1 |
|
decreases response to substance |
ISO |
10 |
39,220,600 |
39,227,602 |
RGD:6480464 |
CTD |
| G |
Irf1 |
interferon regulatory factor 1 |
|
increases expression |
EXP |
10 |
39,220,600 |
39,227,602 |
RGD:6480464 |
CTD |
| G |
Irf1 |
interferon regulatory factor 1 |
|
increases expression |
ISO |
10 |
39,220,600 |
39,227,602 |
RGD:6480464 |
CTD |
| G |
Irs1 |
insulin receptor substrate 1 |
|
multiple interactions |
EXP |
9 |
81,585,251 |
81,638,071 |
RGD:6480464 |
CTD |
| G |
Irs1 |
insulin receptor substrate 1 |
|
increases phosphorylation |
EXP |
9 |
81,585,251 |
81,638,071 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases phosphorylation |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Junb |
jun B proto-oncogene |
|
increases expression |
EXP |
19 |
24,831,536 |
24,833,320 |
RGD:6480464 |
CTD |
| G |
Kif3b |
kinesin family member 3B |
|
increases mutagenesis |
ISO |
3 |
143,642,175 |
143,681,902 |
RGD:6480464 |
CTD |
| G |
Kitlg |
KIT ligand |
|
decreases expression |
ISO |
7 |
37,714,157 |
37,795,722 |
RGD:6480464 |
CTD |
| G |
Kitlg |
KIT ligand |
|
multiple interactions |
ISO |
7 |
37,714,157 |
37,795,722 |
RGD:6480464 |
CTD |
| G |
Klk1 |
kallikrein 1 |
|
increases expression |
ISO |
1 |
94,624,828 |
94,628,822 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
increases mutagenesis |
ISO |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
decreases response to substance |
EXP |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
increases mutagenesis |
ISO |
4 |
182,869,242 |
182,895,106 |
RGD:6480464 |
CTD |
| G |
Lcn2 |
lipocalin 2 |
|
increases expression |
EXP |
3 |
11,511,402 |
11,514,747 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
multiple interactions |
ISO |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
increases expression |
ISO |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
LOC100360337 |
zinc finger protein 128-like |
|
increases expression |
EXP |
1 |
72,788,832 |
72,801,150 |
RGD:6480464 |
CTD |
| G |
Ltb |
lymphotoxin beta (TNF superfamily, member 3) |
|
decreases response to substance |
ISO |
20 |
3,666,524 |
3,668,369 |
RGD:6480464 |
CTD |
| G |
Madcam1 |
mucosal vascular addressin cell adhesion molecule 1 |
|
increases expression |
ISO |
7 |
11,553,219 |
11,556,621 |
RGD:6480464 |
CTD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
multiple interactions |
EXP |
8 |
68,379,074 |
68,451,554 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases response to substance |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
multiple interactions |
EXP |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases response to substance |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
decreases response to substance |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases activity |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases activity |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases phosphorylation |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mbp |
myelin basic protein |
|
decreases expression |
EXP |
18 |
78,943,608 |
79,057,329 |
RGD:6480464 |
CTD |
| G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
increases expression |
EXP |
8 |
91,839,845 |
91,955,917 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
increases alkylation |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
multiple interactions |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases response to substance |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
multiple interactions |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases response to substance |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
multiple interactions |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases response to substance |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases response to substance |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases response to substance |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases response to substance |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mlf1 |
myeloid leukemia factor 1 |
|
increases expression |
EXP |
2 |
157,230,783 |
157,263,847 |
RGD:6480464 |
CTD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
multiple interactions |
ISO |
8 |
115,616,396 |
115,653,471 |
RGD:6480464 |
CTD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
multiple interactions |
ISO |
8 |
115,616,396 |
115,653,471 |
RGD:6480464 |
CTD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
affects response to substance |
ISO |
8 |
115,616,396 |
115,653,471 |
RGD:6480464 |
CTD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
increases expression |
EXP |
8 |
4,315,601 |
4,329,146 |
RGD:6480464 |
CTD |
| G |
Mpc1 |
mitochondrial pyruvate carrier 1 |
|
increases expression |
EXP |
1 |
47,077,723 |
47,089,344 |
RGD:6480464 |
CTD |
| G |
Mpg |
N-methylpurine-DNA glycosylase |
|
decreases response to substance |
ISO |
10 |
15,643,334 |
15,649,561 |
RGD:6480464 |
CTD |
| G |
Mpg |
N-methylpurine-DNA glycosylase |
|
increases response to substance |
ISO |
10 |
15,643,334 |
15,649,561 |
RGD:6480464 |
CTD |
| G |
Mpg |
N-methylpurine-DNA glycosylase |
|
increases response to substance |
ISO |
10 |
15,643,334 |
15,649,561 |
RGD:6480464 |
CTD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
multiple interactions |
ISO |
6 |
11,199,906 |
11,258,350 |
RGD:6480464 |
CTD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
multiple interactions |
ISO |
6 |
11,199,906 |
11,258,350 |
RGD:6480464 |
CTD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
affects response to substance |
ISO |
6 |
11,199,906 |
11,258,350 |
RGD:6480464 |
CTD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
increases response to substance |
ISO |
6 |
11,199,906 |
11,258,350 |
RGD:6480464 |
CTD |
| G |
Msh6 |
mutS homolog 6 (E. coli) |
|
multiple interactions |
ISO |
6 |
11,525,292 |
11,542,592 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
multiple interactions |
ISO |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
increases expression |
ISO |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
|
decreases expression |
EXP |
4 |
117,517,611 |
117,529,128 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myo5a |
myosin VA |
|
increases mutagenesis |
ISO |
8 |
79,909,224 |
80,027,290 |
RGD:6480464 |
CTD |
| G |
Myo5a |
myosin VA |
|
increases mutagenesis |
ISO |
8 |
79,909,224 |
80,027,290 |
RGD:6480464 |
CTD |
| G |
Ncor2 |
nuclear receptor co-repressor 2 |
|
affects expression |
EXP |
12 |
32,617,643 |
32,725,753 |
RGD:6480464 |
CTD |
| G |
Nes |
nestin |
|
increases expression |
EXP |
2 |
180,051,907 |
180,060,947 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases expression |
EXP |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nnat |
neuronatin |
|
decreases expression |
EXP |
3 |
148,269,404 |
148,271,781 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nrxn3 |
neurexin 3 |
|
decreases expression |
EXP |
6 |
112,273,955 |
113,905,437 |
RGD:6480464 |
CTD |
| G |
Oaf |
OAF homolog (Drosophila) |
|
increases expression |
EXP |
8 |
46,224,861 |
46,242,832 |
RGD:6480464 |
CTD |
| G |
Ogfrl1 |
opioid growth factor receptor-like 1 |
|
increases expression |
EXP |
9 |
22,233,997 |
22,247,453 |
RGD:6480464 |
CTD |
| G |
Opn4 |
opsin 4 |
|
decreases expression |
EXP |
16 |
10,249,756 |
10,258,923 |
RGD:6480464 |
CTD |
| G |
Parg |
poly (ADP-ribose) glycohydrolase |
|
increases response to substance |
ISO |
16 |
7,689,492 |
7,798,104 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases response to substance |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
affects response to substance |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases activity |
EXP |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
EXP |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
|
increases response to substance |
ISO |
15 |
26,790,296 |
26,801,086 |
RGD:6480464 |
CTD |
| G |
Pc |
pyruvate carboxylase |
|
increases expression |
EXP |
1 |
207,112,853 |
207,212,737 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
multiple interactions |
ISO |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
increases expression |
EXP |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pdk1 |
pyruvate dehydrogenase kinase, isozyme 1 |
|
increases expression |
EXP |
3 |
54,292,076 |
54,319,242 |
RGD:6480464 |
CTD |
| G |
Perp |
PERP, TP53 apoptosis effector |
|
increases expression |
ISO |
1 |
13,976,356 |
13,988,803 |
RGD:6480464 |
CTD |
| G |
Piezo1 |
piezo-type mechanosensitive ion channel component 1 |
|
increases expression |
EXP |
19 |
52,770,967 |
52,834,347 |
RGD:6480464 |
CTD |
| G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
|
multiple interactions |
EXP |
X |
50,797,413 |
50,812,217 |
RGD:6480464 |
CTD |
| G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
|
multiple interactions |
EXP |
X |
50,797,413 |
50,812,217 |
RGD:6480464 |
CTD |
| G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
|
increases mutagenesis |
EXP |
X |
50,797,413 |
50,812,217 |
RGD:6480464 |
CTD |
| G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
|
increases mutagenesis |
EXP |
X |
50,797,413 |
50,812,217 |
RGD:6480464 |
CTD |
| G |
Pkib |
protein kinase (cAMP-dependent, catalytic) inhibitor beta |
|
increases expression |
EXP |
20 |
36,655,506 |
36,750,474 |
RGD:6480464 |
CTD |
| G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
|
increases expression |
ISO |
18 |
62,914,845 |
62,918,832 |
RGD:6480464 |
CTD |
| G |
Pms2 |
postmeiotic segregation increased 2 (S. cerevisiae) |
|
affects response to substance |
ISO |
12 |
11,004,507 |
11,028,754 |
RGD:6480464 |
CTD |
| G |
Pms2 |
postmeiotic segregation increased 2 (S. cerevisiae) |
|
multiple interactions |
ISO |
12 |
11,004,507 |
11,028,754 |
RGD:6480464 |
CTD |
| G |
Pms2 |
postmeiotic segregation increased 2 (S. cerevisiae) |
|
affects response to substance |
ISO |
12 |
11,004,507 |
11,028,754 |
RGD:6480464 |
CTD |
| G |
Pms2 |
postmeiotic segregation increased 2 (S. cerevisiae) |
|
increases response to substance |
ISO |
12 |
11,004,507 |
11,028,754 |
RGD:6480464 |
CTD |
| G |
Polb |
polymerase (DNA directed), beta |
|
increases response to substance |
ISO |
16 |
73,864,702 |
73,888,011 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases response to substance |
ISO |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Prune |
prune exopolyphosphatase |
|
increases mutagenesis |
ISO |
2 |
190,165,356 |
190,192,807 |
RGD:6480464 |
CTD |
| G |
Pten |
phosphatase and tensin homolog |
|
decreases expression |
ISO |
1 |
236,771,027 |
236,837,261 |
RGD:6480464 |
CTD |
| G |
Pvrl1 |
poliovirus receptor-related 1 |
|
decreases expression |
EXP |
8 |
46,739,657 |
46,799,051 |
RGD:6480464 |
CTD |
| G |
Rara |
retinoic acid receptor, alpha |
|
increases mutagenesis |
ISO |
10 |
87,740,479 |
87,753,265 |
RGD:6480464 |
CTD |
| G |
Rara |
retinoic acid receptor, alpha |
|
multiple interactions |
EXP |
10 |
87,740,479 |
87,753,265 |
RGD:6480464 |
CTD |
| G |
Rara |
retinoic acid receptor, alpha |
|
increases expression |
EXP |
10 |
87,740,479 |
87,753,265 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
increases phosphorylation |
EXP |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
Rbm4 |
RNA binding motif protein 4 |
|
increases mutagenesis |
ISO |
1 |
207,394,470 |
207,403,393 |
RGD:6480464 |
CTD |
| G |
Rbp4 |
retinol binding protein 4, plasma |
|
increases expression |
EXP |
1 |
242,443,795 |
242,450,997 |
RGD:6480464 |
CTD |
| G |
Reg1a |
regenerating islet-derived 1 alpha |
|
increases expression |
ISO |
4 |
112,386,071 |
112,389,205 |
RGD:6480464 |
CTD |
| G |
Reg3b |
regenerating islet-derived 3 beta |
|
increases expression |
ISO |
4 |
112,355,773 |
112,359,011 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
affects activity |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
affects localization |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
decreases expression |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
decreases expression |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
increases expression |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
EXP |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rfx4 |
regulatory factor X, 4 (influences HLA class II expression) |
|
increases mutagenesis |
ISO |
7 |
20,976,369 |
21,052,088 |
RGD:6480464 |
CTD |
| G |
Rnase1 |
ribonuclease, RNase A family, 1 (pancreatic) |
|
increases expression |
ISO |
15 |
27,123,440 |
27,124,991 |
RGD:6480464 |
CTD |
| G |
RT1-A2 |
RT1 class Ia, locus A2 |
|
increases expression |
EXP |
20 |
5,021,816 |
5,025,341 |
RGD:6480464 |
CTD |
| G |
RT1-EC2 |
RT1 class Ib, locus EC2 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Rxrg |
retinoid X receptor gamma |
|
affects expression |
EXP |
13 |
83,256,823 |
83,298,724 |
RGD:6480464 |
CTD |
| G |
S100a3 |
S100 calcium binding protein A3 |
|
increases expression |
EXP |
2 |
182,881,054 |
182,883,821 |
RGD:6480464 |
CTD |
| G |
Scg2 |
secretogranin II |
|
increases expression |
EXP |
9 |
78,762,661 |
78,767,970 |
RGD:6480464 |
CTD |
| G |
Scn10a |
sodium channel, voltage-gated, type X, alpha subunit |
|
decreases expression |
EXP |
8 |
124,578,222 |
124,690,458 |
RGD:6480464 |
CTD |
| G |
Slc16a12 |
solute carrier family 16, member 12 (monocarboxylic acid transporter 12) |
|
increases mutagenesis |
ISO |
1 |
238,643,040 |
238,665,699 |
RGD:6480464 |
CTD |
| G |
Slc26a4 |
solute carrier family 26, member 4 |
|
multiple interactions |
EXP |
6 |
49,389,212 |
49,427,000 |
RGD:6480464 |
CTD |
| G |
Smad4 |
SMAD family member 4 |
|
increases response to substance |
ISO |
18 |
70,432,705 |
70,461,541 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
affects metabolic processing |
ISO |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
ISO |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sphk1 |
sphingosine kinase 1 |
|
increases expression |
EXP |
10 |
106,641,509 |
106,645,579 |
RGD:6480464 |
CTD |
| G |
Spink4 |
serine peptidase inhibitor, Kazal type 4 |
|
increases mutagenesis |
ISO |
5 |
58,314,305 |
58,325,973 |
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Spry2 |
sprouty homolog 2 (Drosophila) |
|
increases expression |
EXP |
15 |
90,009,109 |
90,011,940 |
RGD:6480464 |
CTD |
| G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
|
increases cleavage |
EXP |
3 |
8,956,380 |
9,021,831 |
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
multiple interactions |
EXP |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Src |
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) |
|
increases expression |
EXP |
3 |
148,157,256 |
148,170,524 |
RGD:6480464 |
CTD |
| G |
Stat4 |
signal transducer and activator of transcription 4 |
|
increases response to substance |
ISO |
9 |
46,510,251 |
46,650,076 |
RGD:6480464 |
CTD |
| G |
Stmn1 |
stathmin 1 |
|
increases expression |
EXP |
5 |
153,226,420 |
153,232,084 |
RGD:6480464 |
CTD |
| G |
Syp |
synaptophysin |
|
affects expression |
EXP |
X |
26,890,307 |
26,905,319 |
RGD:6480464 |
CTD |
| G |
Terc |
telomerase RNA component |
|
affects response to substance |
ISO |
2 |
117,234,446 |
117,234,833 |
RGD:6480464 |
CTD |
| G |
Tff2 |
trefoil factor 2 |
|
increases expression |
ISO |
20 |
9,492,341 |
9,510,558 |
RGD:6480464 |
CTD |
| G |
Tgif1 |
TGFB-induced factor homeobox 1 |
|
increases expression |
EXP |
9 |
110,043,164 |
110,052,783 |
RGD:6480464 |
CTD |
| G |
Thpo |
thrombopoietin |
|
multiple interactions |
ISO |
11 |
82,412,552 |
82,417,807 |
RGD:6480464 |
CTD |
| G |
Thpo |
thrombopoietin |
|
increases expression |
ISO |
11 |
82,412,552 |
82,417,807 |
RGD:6480464 |
CTD |
| G |
Thra |
thyroid hormone receptor alpha |
|
affects expression |
EXP |
10 |
87,514,443 |
87,542,306 |
RGD:6480464 |
CTD |
| G |
Thrb |
thyroid hormone receptor beta |
|
affects expression |
EXP |
15 |
9,282,845 |
9,345,506 |
RGD:6480464 |
CTD |
| G |
Thrsp |
thyroid hormone responsive |
|
decreases expression |
EXP |
1 |
154,647,339 |
154,651,663 |
RGD:6480464 |
CTD |
| G |
Thrsp |
thyroid hormone responsive |
|
increases expression |
EXP |
1 |
154,647,339 |
154,651,663 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
increases expression |
EXP |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Tinagl1 |
tubulointerstitial nephritis antigen-like 1 |
|
increases expression |
EXP |
5 |
149,198,274 |
149,207,653 |
RGD:6480464 |
CTD |
| G |
Tkt |
transketolase |
|
increases expression |
EXP |
16 |
5,908,759 |
5,933,695 |
RGD:6480464 |
CTD |
| G |
Tmem69 |
transmembrane protein 69 |
|
increases mutagenesis |
ISO |
5 |
136,831,040 |
136,834,619 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b |
|
decreases expression |
EXP |
7 |
90,606,424 |
90,634,431 |
RGD:6480464 |
CTD |
| G |
Tnfrsf12a |
tumor necrosis factor receptor superfamily, member 12a |
|
increases expression |
EXP |
10 |
12,940,334 |
12,942,343 |
RGD:6480464 |
CTD |
| G |
Tnip2 |
TNFAIP3 interacting protein 2 |
|
increases expression |
EXP |
14 |
81,870,935 |
81,888,169 |
RGD:6480464 |
CTD |
| G |
Top3b |
topoisomerase (DNA) III beta |
|
decreases expression |
ISO |
11 |
86,116,936 |
86,145,314 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases phosphorylation |
EXP |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases phosphorylation |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases response to substance |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
affects response to substance |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases phosphorylation |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Trg |
T cell receptor gamma locus |
|
increases mutagenesis |
ISO |
17 |
53,496,412 |
53,528,047 |
RGD:6480464 |
CTD |
| G |
Tspo |
translocator protein |
|
increases expression |
EXP |
7 |
121,597,084 |
121,599,342 |
RGD:6480464 |
CTD |
| G |
Tyr |
tyrosinase |
|
increases mutagenesis |
ISO |
1 |
143,641,257 |
143,746,315 |
RGD:6480464 |
CTD |
| G |
Tyrp1 |
tyrosinase-related protein 1 |
|
increases mutagenesis |
ISO |
5 |
99,518,306 |
99,537,289 |
RGD:6480464 |
CTD |
| G |
Ubac2 |
UBA domain containing 2 |
|
increases mutagenesis |
ISO |
15 |
107,009,509 |
107,125,419 |
RGD:6480464 |
CTD |
| G |
Ube2j1 |
ubiquitin-conjugating enzyme E2, J1 |
|
increases expression |
EXP |
5 |
49,317,881 |
49,337,258 |
RGD:6480464 |
CTD |
| G |
Upp1 |
uridine phosphorylase 1 |
|
increases expression |
EXP |
14 |
89,651,264 |
89,669,630 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Wnt5a |
wingless-type MMTV integration site family, member 5A |
|
increases expression |
EXP |
16 |
3,782,025 |
3,799,625 |
RGD:6480464 |
CTD |
| G |
Xiap |
X-linked inhibitor of apoptosis |
|
decreases response to substance |
ISO |
X |
3,011,520 |
3,047,798 |
RGD:6480464 |
CTD |
| G |
Xrcc5 |
X-ray repair complementing defective repair in Chinese hamster cells 5 |
|
increases mutagenesis |
ISO |
9 |
71,472,459 |
71,581,936 |
RGD:6480464 |
CTD |
Term paths to the root
|